The Oncology Brothers—Rahul Gosain, MD, of the University of Rochester, and Rohit Gosain, MD, of the UPMC Hillman Cancer Center, are joined by Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute, to discuss the HER2CLIMB-02 study presented at SABCS. The study assessed the use of trastuzumab plus tucatinib in patients with HER2+ metastatic breast cancer and observed a 24.1% reduced risk of progression or death with the combination versus trastuzumab plus placebo. The trio then discussed how this treatment option fits into the HER2+ breast cancer landscape.

свернуть